trial

Escitalopram in Schizophrenia in OCD- Open Label Study

NCTId NCT00456937
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 15 (estimated)
Sponsored by BeerYaakov Mental Health Center
Primary completion 2008-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
15 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2006-07
Primary completion
2008-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
escitalopram

Sponsors

BeerYaakov Mental Health CenterLead Sponsor
Lundbeck Canada Inc.Collaborator

Investigators

1
Rafael Octavio Stryjer, M.D.Principal Investigator

Sites

1 total
Beer Yaakov, Israel

Facts & assertions

4 sourced
Enrollment
15
Phase
PHASE4
Primary Completion Date
2008-09
Status
COMPLETED
relationships
The graph out of here
drug
escitalopram
drug
lead_sponsor
BeerYaakov Mental Health Center
company
collaborator
Lundbeck Canada Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Rafael Octavio Stryjer, M.D.
person